# Rezolute, Inc.: financial statements, quarterly

RZLT · Nasdaq · CIK 1509261 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/rzlt.md) · [Financials](/companies/rzlt/financials.md) · [Filings](/companies/rzlt/filings.md) · [Insiders](/companies/rzlt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/rzlt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [12.2](/filings/0001558370-24-014893.md) | [12.0](/filings/0001558370-25-000867.md) | [12.4](/filings/0001558370-25-007582.md) | [19.1 d](/filings/0001104659-25-090848.md) | [12.8](/filings/0001104659-25-107781.md) | [12.6](/filings/0001104659-26-014334.md) | [15.3](/filings/0001104659-26-059422.md) | [20.9 d](/filings/0001104659-26-110420.md) | [13.1](/filings/0001104659-25-107781.md) | [14.3](/filings/0001104659-26-014334.md) | [11.4](/filings/0001104659-26-059422.md) | [14.9 d](/filings/0001104659-26-110420.md) |
| Operating income | $m | [(15.9)](/filings/0001558370-24-014893.md) | [(15.2)](/filings/0001558370-25-000867.md) | [(16.2)](/filings/0001558370-25-007582.md) | [(23.1) d](/filings/0001104659-25-090848.md) | [(16.9)](/filings/0001104659-25-107781.md) | [(17.1)](/filings/0001104659-26-014334.md) | [(20.0)](/filings/0001104659-26-059422.md) | [(25.9) d](/filings/0001104659-26-110420.md) | [(19.8)](/filings/0001104659-25-107781.md) | [(24.2)](/filings/0001104659-26-014334.md) | [(17.4)](/filings/0001104659-26-059422.md) | [(21.6) d](/filings/0001104659-26-110420.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [(14.5)](/filings/0001558370-24-014893.md) | [(13.9)](/filings/0001558370-25-000867.md) | [(17.1)](/filings/0001558370-25-007582.md) | [(23.0) d](/filings/0001104659-25-090848.md) | [(15.4)](/filings/0001104659-25-107781.md) | [(15.7)](/filings/0001104659-26-014334.md) | [(18.9)](/filings/0001104659-26-059422.md) | [(24.4) d](/filings/0001104659-26-110420.md) | [(18.2)](/filings/0001104659-25-107781.md) | [(22.8)](/filings/0001104659-26-014334.md) | [(16.2)](/filings/0001104659-26-059422.md) | [(20.5) d](/filings/0001104659-26-110420.md) |
| Diluted EPS | $ per share | [(0.28)](/filings/0001558370-24-014893.md) | [(0.27)](/filings/0001558370-25-000867.md) | [(0.34)](/filings/0001558370-25-007582.md) | not reported | [(0.22)](/filings/0001104659-25-107781.md) | [(0.22)](/filings/0001104659-26-014334.md) | [(0.27)](/filings/0001104659-26-059422.md) | not reported | [(0.18)](/filings/0001104659-25-107781.md) | [(0.22)](/filings/0001104659-26-014334.md) | [(0.16)](/filings/0001104659-26-059422.md) | not reported |
| Basic EPS | $ per share | [(0.28)](/filings/0001558370-24-014893.md) | [(0.27)](/filings/0001558370-25-000867.md) | [(0.34)](/filings/0001558370-25-007582.md) | not reported | [(0.22)](/filings/0001104659-25-107781.md) | [(0.22)](/filings/0001104659-26-014334.md) | [(0.27)](/filings/0001104659-26-059422.md) | not reported | [(0.18)](/filings/0001104659-25-107781.md) | [(0.22)](/filings/0001104659-26-014334.md) | [(0.16)](/filings/0001104659-26-059422.md) | not reported |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [8.1](/filings/0001558370-23-018839.md) | [12.5](/filings/0001558370-24-001069.md) | [5.9](/filings/0001558370-24-008294.md) | [70.4](/filings/0001104659-25-090848.md) | [10.5](/filings/0001558370-24-014893.md) | [8.9](/filings/0001558370-25-000867.md) | [14.6](/filings/0001558370-25-007582.md) | [94.1](/filings/0001104659-26-110420.md) | [9.1](/filings/0001104659-25-107781.md) | [11.9](/filings/0001104659-26-014334.md) | [11.2](/filings/0001104659-26-059422.md) | [10.6](/filings/0001104659-26-110420.md) |
| Current assets | $m | [103](/filings/0001558370-23-018839.md) | [96.1](/filings/0001558370-24-001069.md) | [82.2](/filings/0001558370-24-008294.md) | [129](/filings/0001104659-25-090848.md) | [110](/filings/0001558370-24-014893.md) | [98.7](/filings/0001558370-25-000867.md) | [88.7](/filings/0001558370-25-007582.md) | [171](/filings/0001104659-26-110420.md) | [155](/filings/0001104659-25-107781.md) | [135](/filings/0001104659-26-014334.md) | [122](/filings/0001104659-26-059422.md) | [111](/filings/0001104659-26-110420.md) |
| Total assets | $m | [113](/filings/0001558370-23-018839.md) | [102](/filings/0001558370-24-001069.md) | [87.7](/filings/0001558370-24-008294.md) | [133](/filings/0001104659-25-090848.md) | [123](/filings/0001558370-24-014893.md) | [112](/filings/0001558370-25-000867.md) | [94.7](/filings/0001558370-25-007582.md) | [175](/filings/0001104659-26-110420.md) | [159](/filings/0001104659-25-107781.md) | [139](/filings/0001104659-26-014334.md) | [125](/filings/0001104659-26-059422.md) | [113](/filings/0001104659-26-110420.md) |
| Current liabilities | $m | [7.2](/filings/0001558370-23-018839.md) | [8.0](/filings/0001558370-24-001069.md) | [7.0](/filings/0001558370-24-008294.md) | [9.6](/filings/0001104659-25-090848.md) | [8.0](/filings/0001558370-24-014893.md) | [10.6](/filings/0001558370-25-000867.md) | [10.5](/filings/0001558370-25-007582.md) | [11.9](/filings/0001104659-26-110420.md) | [10.2](/filings/0001104659-25-107781.md) | [9.5](/filings/0001104659-26-014334.md) | [7.7](/filings/0001104659-26-059422.md) | [11.4](/filings/0001104659-26-110420.md) |
| Total liabilities | $m | [9.4](/filings/0001558370-23-018839.md) | [10.4](/filings/0001558370-24-001069.md) | [16.9](/filings/0001558370-24-008294.md) | [11.7](/filings/0001104659-25-090848.md) | [10.0](/filings/0001558370-24-014893.md) | [12.4](/filings/0001558370-25-000867.md) | [12.2](/filings/0001558370-25-007582.md) | [13.4](/filings/0001104659-26-110420.md) | [11.5](/filings/0001104659-25-107781.md) | [10.6](/filings/0001104659-26-014334.md) | [8.6](/filings/0001104659-26-059422.md) | [12.2](/filings/0001104659-26-110420.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [104](/filings/0001558370-25-000867.md) | [91.7](/filings/0001558370-25-007582.md) | [70.9](/filings/0001558370-25-007582.md) | [121](/filings/0001104659-26-110420.md) | [113](/filings/0001104659-26-014334.md) | [99.6](/filings/0001104659-26-059422.md) | [82.6](/filings/0001104659-26-059422.md) | [162](/filings/0001104659-26-110420.md) | [147](/filings/0001104659-26-014334.md) | [128](/filings/0001104659-26-059422.md) | [117](/filings/0001104659-26-059422.md) | [101](/filings/0001104659-26-110420.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(10.6)](/filings/0001558370-24-014893.md) | [(13.0) d](/filings/0001558370-25-000867.md) | [(15.2) d](/filings/0001558370-25-007582.md) | [(18.5) d](/filings/0001104659-25-090848.md) | [(16.0)](/filings/0001104659-25-107781.md) | [(13.7) d](/filings/0001104659-26-014334.md) | [(17.4) d](/filings/0001104659-26-059422.md) | [(22.0) d](/filings/0001104659-26-110420.md) | [(17.4)](/filings/0001104659-25-107781.md) | [(20.3) d](/filings/0001104659-26-014334.md) | [(13.7) d](/filings/0001104659-26-059422.md) | [(13.1) d](/filings/0001104659-26-110420.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | [0.0 d](/filings/0001104659-25-090848.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [50.5](/filings/0001558370-23-018839.md) | [51.4](/filings/0001558370-24-001069.md) | [51.4](/filings/0001558370-24-008294.md) | [51.4](/filings/0001558370-24-014893.md) | [51.4](/filings/0001558370-25-000867.md) | [50.8](/filings/0001558370-25-007582.md) | [69.7](/filings/0001104659-25-107781.md) | [69.9](/filings/0001104659-26-014334.md) | [70.0](/filings/0001104659-26-059422.md) | [103](/filings/0001104659-25-107781.md) | [104](/filings/0001104659-26-014334.md) | [104](/filings/0001104659-26-059422.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 96,722,333 at 2026-09-21, from the cover of the [10-K filed 2026-09-24](/filings/0001104659-26-110420.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.